New pill takes on Hard-to-Treat prostate cancer

NCT ID NCT06155084

Recruiting now Disease control Sponsor: Hinova Pharmaceuticals Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests an experimental oral drug called HP518 in 84 men with metastatic castration-resistant prostate cancer that has spread and stopped responding to standard hormone therapy. The trial has two parts: first, finding the safest dose, then checking how well that dose controls the cancer. Researchers will monitor side effects, drug levels in the blood, and tumor markers like PSA.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HP518 (oral drug)
What this could lead to: If it works, this could point toward a new oral treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is an early phase 1/2 trial with only 84 participants, so it is too soon to know if HP518 is truly effective or safe. Side effects are still being identified, and the drug may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Beijing Cancer Hospital
RECRUITING

Beijing, Beijing Municipality, China
Beijing Friendship Hospital, Capital Medical University
RECRUITING

Beijing, Beijing Municipality, China
Chongqing University Cancer Hospital
RECRUITING

Chongqing, Chongqing Municipality, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, China
Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, China
Lanzhou University Second Hospital
RECRUITING

Lanzhou, Gansu, China
Liaoning Cancer Hospital & Institute
RECRUITING

Shenyang, Liaoning, China
Mianyang Central Hospital
RECRUITING

Mianyang, Sichuan, China
Shandong Provincial Hospital
RECRUITING

Jinan, Shandong, China
Shanghai Tenth People's Hospital
RECRUITING

Shanghai, Shanghai Municipality, China
Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital
RECRUITING

Chengdu, Sichuan, China
The Affiliated Hospital Of Guizhou Medical University
RECRUITING

Guiyang, Guizhou, China
The Affiliated Hospital Of Qingdao University
RECRUITING

Qingdao, Shandong, China
The Affiliated Hospital Of School Of Medicine Of Ningbo University
RECRUITING

Ningbo, Zhejiang, China
The Affiliated Hospital Of Southwest Medical University
RECRUITING

Luzhou, Sichuan, China
The First Affiliated Hospital Of Nanchang University
RECRUITING

Nanchang, Jiangxi, China
The First Affiliated Hospital Of Xi'An Jiaotong Univeristy
RECRUITING

Xi’an, Shanxi, China
The First Affiliated Hospital Of Xiamen Univeristy
NOT_YET_RECRUITING

Xiamen, Fujian, China
The First Affiliated Hospital of Wenzhou Medical University
RECRUITING

Wenzhou, Zhejiang, China
The Second Affiliated Hospital Of Chongqing Medical University
RECRUITING

Chongqing, Chongqing Municipality, China
The Second Affiliated Hospital Of Kunming Medical University
RECRUITING

Kunming, Yunnan, China
The Second Hospital Of Anhui Medical University
RECRUITING

Hefei, Anhui, China
The Third Affiliated Hospital of Southern Medical University
RECRUITING

Guangzhou, Guangdong, China
Tongji Hospital
RECRUITING

Wuhan, Hubei, China
West China Hospital Of Sichuan University
RECRUITING

Chengdu, Sichuan, China
Yantai Yuhuangding Hospital
RECRUITING

Yantai, Shandong, China
Zhengzhou Central Hospital
RECRUITING

Zhengzhou, Henan, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.